Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752458 | 0.92 | LMNA (0.43) | TSHRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL6314520 | 0.92 | LMNA (0.43) | TSHRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL6309137 | 0.92 | TSHR (0.44) | TSHRGAAMAPK1ALDH1A1KDM4E | |
| SCHEMBL6314687 | 0.88 | LMNA (0.46) | TSHRGAAMAPK1ALDH1A1KDM4E | |
| SCHEMBL7071510 | 0.88 | LMNA (0.46) | TSHRGAAMAPK1ALDH1A1KDM4E | |
| SCHEMBL6305853 | 0.88 | LMNA (0.46) | TSHRGAAMAPK1ALDH1A1KDM4E | |
| SCHEMBL6314378 | 0.85 | BRAF (0.44) | TSHRGAAMAPK1ALDH1A1MAPT | |
| SCHEMBL6308373 | 0.79 | EGFR (0.36) | GAAALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL7079694 | 0.78 | LMNA (0.45) | TSHRGAAMAPK1ALDH1A1KDM4E | |
| SCHEMBL6314372 | 0.78 | LMNA (0.45) | TSHRGAAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1489596-A | Alpha-substituted beta-aminoethylphosphonates | �Ʒ� | 2004-04-14 | — | — | CN | claimed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | claimed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | claimed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | claimed |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | ILEX PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| CN-1489596-A | Alpha-substituted beta-aminoethylphosphonates | �Ʒ� | 2004-04-14 | — | — | CN | disclosed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | PHAN HIEU TRUNG (CH) | 2003-06-19 | — | — | US | disclosed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | TSHR 4540/4885GAA 873/4885MAPK1 2831/4885 |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | TSHR 4540/4885GAA 873/4885MAPK1 2831/4885 |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | APOB, LDLR, HDLBP | TSHR 4237/4885GAA 2518/4885MAPK1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.